Fennec Pharmaceuticals (NASDAQ:FENC) Versus Candel Therapeutics (NASDAQ:CADL) Critical Comparison
Fennec Pharmaceuticals (NASDAQ:FENC) Versus Candel Therapeutics (NASDAQ:CADL) Critical Comparison
Fennec Pharmaceuticals (NASDAQ:FENC – Get Rating) and Candel Therapeutics (NASDAQ:CADL – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.
Fennec PharmPharmticals(納斯達克代碼：FENC-GET Rating)和Candel Treateutics(納斯達克代碼：CADL-GET Rating)都是小盤醫療公司，但哪一家更好？我們將根據這兩家公司的估值、分析師建議、收益、盈利能力、機構所有權、股息和風險的強弱對它們進行比較。
Institutional & Insider Ownership
機構與內部人持股
43.3% of Fennec Pharmaceuticals shares are owned by institutional investors. Comparatively, 21.1% of Candel Therapeutics shares are owned by institutional investors. 9.4% of Fennec Pharmaceuticals shares are owned by insiders. Comparatively, 44.3% of Candel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Fennec PharmPharmticals 43.3%的股份由機構投資者持有。相比之下，Candel Treateutics 21.1%的股份由機構投資者持有。Fennec PharmPharmticals 9.4%的股份由內部人士持有。相比之下，Candel Treateutics 44.3%的股份由內部人士持有。強大的機構持股表明，大型基金管理公司、對衝基金和捐贈基金相信，一隻股票有望實現長期增長。
Volatility and Risk
波動性和風險
Fennec Pharmaceuticals has a beta of 0.03, suggesting that its share price is 97% less volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of 0.1, suggesting that its share price is 90% less volatile than the S&P 500.
Fennec PharmPharmticals的貝塔係數為0.03，表明其股價的波動性比標準普爾500指數低97%。相比之下，Candel Treateutics的貝塔係數為0.1，這表明其股價的波動性比標準普爾500指數低90%。
Profitability
盈利能力
| Net Margins | Return on Equity | Return on Assets | |
| Fennec Pharmaceuticals | N/A | -214.78% | -97.25% |
| Candel Therapeutics | N/A | -20.18% | -13.13% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 芬內剋制藥公司 | 不適用 | -214.78% | -97.25% |
| 秋茄治療公司 | 不適用 | -20.18% | -13.13% |
Valuation and Earnings
估值和收益
This table compares Fennec Pharmaceuticals and Candel Therapeutics' gross revenue, earnings per share (EPS) and valuation.
此表比較了Fennec製藥公司和Candel治療公司的毛收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fennec Pharmaceuticals | $170,000.00 | 1,483.88 | -$17.35 million | ($0.82) | -11.71 |
| Candel Therapeutics | $130,000.00 | 397.85 | -$36.12 million | ($0.42) | -4.26 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 芬內剋制藥公司 | $170,000.00 | 1,483.88 | -1,735萬美元 | ($0.82) | -11.71 |
| 秋茄治療公司 | $130,000.00 | 397.85 | -3,612萬元 | ($0.42) | -4.26 |
Fennec Pharmaceuticals has higher revenue and earnings than Candel Therapeutics. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.
Fennec製藥公司的收入和收益高於Candel治療公司。Fennec製藥公司的市盈率低於Candel治療公司，這表明它目前是兩隻股票中更負擔得起的一隻。
Analyst Recommendations
分析師建議
This is a summary of current recommendations and price targets for Fennec Pharmaceuticals and Candel Therapeutics, as provided by MarketBeat.com.
這是由MarketBeat.com提供的Fennec製藥公司和Candel治療公司的當前建議和目標價的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fennec Pharmaceuticals | 0 | 0 | 5 | 0 | 3.00 |
| Candel Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 芬內剋制藥公司 | 0 | 0 | 5 | 0 | 3.00 |
| 秋茄治療公司 | 0 | 0 | 3 | 0 | 3.00 |
Fennec Pharmaceuticals presently has a consensus price target of $14.83, indicating a potential upside of 54.51%. Candel Therapeutics has a consensus price target of $10.33, indicating a potential upside of 477.28%. Given Candel Therapeutics' higher probable upside, analysts clearly believe Candel Therapeutics is more favorable than Fennec Pharmaceuticals.
Fennec製藥公司目前的共識目標價為14.83美元，表明潛在上行空間為54.51%。Candel治療公司的共識目標價為10.33美元，這表明潛在的上漲幅度為477.28。鑑於Candel治療公司更有可能上行，分析人士顯然認為Candel治療公司比Fennec製藥公司更有利。
Summary
摘要
Candel Therapeutics beats Fennec Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
Candel Treeutics在兩隻股票比較的11個因素中有6個擊敗了Fennec PharmPharmticals。
About Fennec Pharmaceuticals
關於Fennec製藥公司
(Get Rating)
(獲取評級)
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
生物製藥公司Fennec PharmPharmticals Inc.開發用於美國癌症治療的候選產品。它的主要候選產品是硫代硫酸鈉，已經完成了預防順鉑引起的兒童聽力損失或耳毒性的第三階段臨牀試驗。該公司前身為Adherex Technologies Inc.，2014年9月更名為Fennec PharmPharmticals Inc.。Fennec製藥公司成立於1996年，總部設在北卡羅來納州的研究三角公園。
About Candel Therapeutics
關於秋茄治療公司
(Get Rating)
(獲取評級)
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
Candel治療公司是一家臨牀階段的生物製藥公司，致力於為癌症患者開發免疫療法。該公司開發了CAN-2409，目前正處於治療胰腺癌的第二階段臨牀試驗；治療前列腺癌的第三階段臨牀試驗；以及治療肺癌的第二階段臨牀試驗，以及治療高級別膠質瘤的Ib/II階段臨牀試驗。它還開發了CAN-3110，這是一種治療復發膠質母細胞瘤的I期臨牀試驗。它還開發了啟迪發現平臺，這是一個系統的、基於HSV的迭代發現平臺，利用人類生物學和先進的分析來為實體腫瘤創造新的病毒免疫療法。該公司前身為Advantagene，Inc.，並於2020年11月更名為Candel治療公司。該公司成立於2003年，總部設在馬薩諸塞州的尼達姆。
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受Fennec PharmPharmticals Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Fennec製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。